Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Fecked if I know Hummm, and tbh the SP is disappointing. I thought some fomo might have kicked in. I have kept adding small (1k) amounts. I don’t doubt the results will be excellent but I am bemused by the SP.….
Lor_9, Cryptic Meg says he knows and it’s going to be “epic”.
https://x.com/ophidian18/status/1733042398840647821?s=61&t=yGNoQ6Xj0Lw6rjPJMTuiZA
JT, that is a good point about the wording AS used regarding the DX side. As you rightly say, AS used the term “spin-out” in the interim’s presentation, which is different to a sale.
“…we've also hinted at the potential to spin out the diagnostics business at some point.”
One of the flaws cited in many research papers regarding liquid biopsies is the lack of standardisation. This is something that AGL has sought to address with the Portrait+ Kit.
From the RNS - “performance of current CTC protocols being used by academic and research institutions varies considerably. ANGLE has developed its test for reliable repeatable results with a fully validated, standardised protocol to make it easy for customers……ANGLE's Portrait+ CTC staining kit provides investigators with accurate, repeatable, and precise identification of CTCs and hence has the potential to optimise study protocols and minimise cost.”
And from September’s Interim’s - “it's being offered as a product to be sold to customers around the world, not just from our clinical labs. And here we're taking the antibodies, that we've spent a couple of years working on, optimising these antibodies for the detection of cancer.
And we have basically productised them by lyophilising the antibodies down into essentially a solid powder form which makes them stable, so they can then be shipped, and they can be stored on a shelf. And the idea of this is that all our customers, external third party customers, can use the same antibodies that we've spent a lot of time optimising so they can then get consistent results with all of the other customers out there. And it makes it much, much easier for adoption. Because at the moment prior, to our launch of Portrait+, our customer’s who buy Parsortix have to define their own method to do antibodies and their own process in their lab. And that’s actually quite tricky, which means that the sale of the product is primarily limited to high quality labs, really top notch labs. What we can do now, and our aim is, we can democratise the use of this to make it super easy for anybody to use it. They just get this kit. They follow our instructions and they can then look under the microscope and get their own information. ..”
Courtesy of ADVFN - AGL tweet.
https://x.com/parsortix/status/1730253185522991579?s=67&t=BBb2UcjLDTXOFIzJM-vM6A
“Be the first to learn about our Portrait®+ CTC staining kit during @SABCSSanAntonio, Booth 1432, from 6th - 8th of Dec, and see how together, the illuminating power of CTCs could revolutionize the treatment of breast cancer.”
The below is from 5oleTrader on ADVFN.
One for the diary? Plugging AGL to US investors.I note this coming week on Thursday 30th Nov at 17:00GMT - AGL will be presenting at the Small Cap Growth Virtual Investor Conference.
https://www.virtualinvestorconferences.com/events/event-details/small-cap-growth-virtual-investor-conference-8(VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Bella, I like many of your posts, but I do not think there will be any further Diagnostic acquisitions, AS was clear about this at the AGM.
I also understood the comment you quoted from the RNS to come from the Therapeutics side of the business, not the Diagnostics - “The Company is progressing pre-clinical programmes based on both the pre|CISIONTM and Affimer® platforms and anticipates providing detailed updates on these programmes in the coming months.”
Ditto my earlier quote from the Therapeutics update in the Interims presentation update, which was in relation to the bispecific affirmers “All of those programmes are now in later stage research and we will be publishing the data, let's say, later this year and through into early next year.”
Beinthelead, to be fair to Bella, AS said regarding the affirmers - “All of those programmes are now in later stage research and we will be publishing the data, let's say, later this year and through into early next year.” (Approx 31:30 into the Interims presentation). So I don’t think Bella is trying to wind people up.
PL75, I think this sums up Hurst (what on earth possessed Oph to ride on his donkey to defend Hurst’s honour? Bizarre).
We know, there are known knowns;
there are things we know we know.
We also know there are known unknowns;
that is to say we know there are some things we do not know.
But there are also unknown unknowns—the ones we don't know we don't know.
(Donald Rumsfeld)
Ophidian quoting Churchill.
What “incontrovertible truth” are you talking about Oph? That you back stabbed Albert who did his best to keep the peace amongst the acrimony that your rudeness and ego created. That you engineered the removal of decent posters and people like Ben Harper who stood up to you? That you posted out of malice a list of shareholders because you/your ego were excluded from the TG meeting with AS? I could go on but the list would be too long.
Beinthelead, “It’s not yet started. As much as the TG group would have people believe.” What is the basis please for your post re the TG group? I think the TG meeting notes only said it was due to start soon.
But I agree it hasn’t started yet , because surely given its importance, the company would RNS its commencement? But that’s just an opinion on my part.
“I think it is just another example of the usual slack/ambiguous language from Ambiguity Smith.” I agree BV, some of what AS says is open to interpretation.
In terms of the fortnightly study, AS also used the word “alongside” - “So what we plan to do now is to run alongside the last cohort in the phase 1a three-weekly dosing, a fortnightly dosing group.” (Interims Presentation).
Either way, in parallel or to coincide with end of C7, we should hear news soon (just not on the 21st, I can’t believe that Sujood got that wrong, that’s very unusual).
Hi Bantham, thanks for your considered reply and I retract what I say in regard to yourself. My apologies. Although my point remains in regard to some ex-investors who repeatedly air their grievances, almost obsessively, and posters (especially on ADVFN) who just want a good stir.
I’m certainly not blind to the shortcomings of AN. Two revenue warnings, lack of significant commercial deals and missed timelines are not a good look. If we don’t get the results published before the year end of the first molecular third party analysis (as per the business update RNS) then I am also out. I will finally have had enough.
Bantham, I don’t get the compulsion to come back on a board after you have sold. Say what you have to and then move on. I think it might have been Dave, on ADVFN , who said if he sold he didnt post anymore, it was bad manners. I have paraphrased, but the sentiment is the same.
I have sold shares at a loss, POLX most recently. I haven’t looked at the SP since and I would only comment on it if I came across some research that I thought would be genuinely useful. It didn’t turn out how I hoped, but I have accepted that and left. Why feel the need to come back on the AGL board?
I did have a wry smile to myself when CF mentioned in the Q&A that he gets some criticism for “maybe over-hype.” I wonder why CF 🤔. But fair play to him he hasn’t sold any of POLB or Hvivo, and said he would like to buy more POLB when he has an opportunity and is “free of inside information”.